Please assess the completion status of the following clinical trial:

Trial Title: Metformin Reduce the Relapse Rate on Patients With B-cell Precursor (Ph+ Negative) Acute Lymphoblastic Leukemia

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* \> 18 years~* de novo B-cell precursor Acute Lymphoblastic Leukemia~* candidates to first line treatment protocol~* ECOG (Eastern Cooperative Oncology Group) Scale of Performance Status 1/2~* Informed Consent Form for genetic analysis samples~* Precursor B Cell Acute Lymphoblastic Leukemia~Exclusion Criteria:~* Diagnose of Acute Myelogenous Leukemia or Biphenotype Leukemia~* Diagnose of type 2 Diabetes Mellitus~* Previous use of Metformin~* Relapsed Acute Leukemia that require treatment protocol to be started~* Intolerance to prednisone~* ECOG Scale of Performance Status 3/4~* T-cell Acute Lymphoblastic Leukemia~* Philadelphia positive Acute Lymphoblastic Leukemia~* Tumor lysis syndrome at diagnose~* Renal Failure (creatinine leve higher than 2mg/dl)~* Several liver damage (\>2 levels de upper normal limit of Aspartate transaminase (AST) and alanine transaminase (ALT)~* Metabolic Acidosis or Lactic Acidosis at diagnose~* Central nervous system infiltration at diagnose~* Extramedullary disease (skin, pleura,eye)~* Active GI bleeding

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- metformin (Type: ACTIVE_COMPARATOR): Metformin 850mg PO three times a day, during the pre-induction with steroids, induction remission, consolidation and maintenance
- No metformin (Type: NO_INTERVENTION): None

Based on this trial design, predict the completion outcome and termination type (if applicable).